Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VGCF fusion proteins

Bioconjugate Chemistry

Volumn 12, Issue 6, 2001, Pages 1066-1073

  Backer, M V ^a   Backer, J M ^a  

^a SIBTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOSYNTHESIS; CELL DEATH; CONTROLLED DRUG DELIVERY; PROTEINS; RNA; TARGETED DRUG DELIVERY;

ANGIOGENESIS; CELL-BINDING; ENDOTHELIAL-CELLS; FUSION PROTEINS; N-GLYCOSIDASE; PROTEIN SYNTHESIS; SHIGA-LIKE TOXINS; SITE-SPECIFIC; VEGFR-2; WILD TYPES;

ENDOTHELIAL CELLS;

ANIMALIA; SUIDAE; SUS SCROFA;

EID: 0035213434     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc015534j     Document Type: Article

References (49)

1. Angiogenesis
2. Signaling vascular morphogenesis and maintenance
3. Angiogenesis in cancer, vascular, rheumatoid and other disease
4. Angiogenesis: New targets for the development of anticancer chemotherapies
5. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
6. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
7. Vascular endothelial growth factor (VEGF) and its receptors
8. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis
9. Regulation of angiogenesis via vascular endothelial growth factor receptors
10. Biological properties of VEGF/VPF receptors
11. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
12. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
13. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
14. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
15. Vascular endothelial growth factor/Vascular permeability factor (VEGF/VPF) in normal and artherosclerotic human arteries
16. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1 positive endothelial cell proliferation in vitro and angiogenesis in vivo
17. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
18. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
19. Pathogenesis of haemolytic uraemic syndrome
20. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections
21. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes
22. Endothelial heterogenecity in Shiga toxin receptors and responses
23. Subunit structure of Shigella cytotoxin
24. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N- glycosideases of 28 S RNA when micro-injected into Xenopus oocytes
25. Minimum domain of the Shiga toxin A subunit required for enzymatic activity
26. Cytotoxicity of a Shiga toxin A subunit-CD4 fusion protein to human immunodeficiency virus-infected cells
27. Purification and characterization of a Shiga toxin A subunit-CD4 fusion protein cytotoxic to human immunodeficiency virus-infected cells
28. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2
29. Functionally active VEGF fusion proteins
30. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells
31. The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain
32. Construction of mutant genes for a nontoxic verotoxin 2 variant (VT2vp1) of Escherichia coli and characterization of purified mutant toxins
33. The RNA-N-glycosidase activity of Shiga-like toxin I: Kinetic parameters of the native and activated toxin
34. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
35. Caspases: The executioners of apoptosis
36. Ribotoxic stress response: Activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA
37. mkp-1 encoding mitogen-activated protein kinase phosphatase 1, a verotoxin 1 responsive gene, detected by differential display reverse transcription-PCR in Caco-2 cells
38. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
39. Diphtheria toxin translocation across endosome membranes. A novel cell permeabilization assay reveals new diphtheria toxin fragments in endocytic vesicles
40. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic
41. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin
42. Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition
43. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins
44. Role of caspases in immunotoxin-induced apoptosis of cancer cells
45. Trichothecene mycotoxins trigger a ribotoxic stress response that activates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase and induces apoptosis
46. Different mechanisms of c-Jun NH(2)-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors
47. The c-Jun N-terminal kinase pathway and apoptotic signaling
48. Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by nontoxic mutant Stx1 which lacks N-glycosidase activity
49. Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6